FPH
11/09/2015 08:58
DIRECTOR
NOT PRICE SENSITIVE
REL: 0858 HRS Fisher & Paykel Healthcare Corporation Limited
DIRECTOR: FPH: Scott St John Appointed to Fisher & Paykel Healthcare Board
SCOTT ST JOHN APPOINTED TO FISHER & PAYKEL HEALTHCARE BOARD
Auckland, New Zealand, 11 September 2015 - Fisher & Paykel Healthcare
Corporation Limited (NZSX:FPH, ASX:FPH) advises that Scott St John has been
appointed as a non-executive director of the company with effect from 1
October 2015.
"We are very pleased to be able to appoint a person of Scott's calibre to the
board. Scott brings with him a wealth of financial skills and extensive
experience that will strengthen and complement those of our board. Scott's
appointment now will ensure a smooth transition when Roger France retires
later this year", said Chairman Tony Carter.
Mr St John was appointed Chief Executive Officer of First NZ Capital in 2002.
He joined First NZ Capital's predecessor company, CS First Boston, in 1993
following seven years at Hendry Hay McIntosh.
Mr St John is Pro Chancellor of the University of Auckland, where he has also
chaired the Finance Committee. He is the former Chair of the Securities
Industry Association, an incorporated body representing the interests of the
sharebroking industry, and a former member of the Government appointed
Capital Markets Development Taskforce and Financial Markets Authority
Establishment Board.
Mr St John is a member of Chartered Accountants Australia and New Zealand and
of the Institute of Finance Professionals of New Zealand (INFINZ).
Mr St John will also succeed Roger France as the Chair of the company's Audit
& Risk Committee.
The Fisher & Paykel Healthcare board has determined that Mr St John will be
an independent director. A resolution to elect Mr St John will be put to
shareholders at the company's next Annual Shareholders' Meeting.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer
of products and systems for use in respiratory care, acute care surgery and
the treatment of obstructive sleep apnea. The company's products are sold in
over 120 countries worldwide. For more information about the company, visit
www.fphcare.com
Contact: Marcus Driller, Investor Relations & Corporate Affairs Manager on
+64 9 574 0110.
End CA:00269993 For:FPH Type:DIRECTOR Time:2015-09-11 08:58:18
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
